Since co-occurrence of ZRSR2 and TET2 mutations have also been observed in BPDCN, our model could also be exploited to explore the biology of dendritic leukemia. The gene discussed is ZRSR2; the disease is CD4+/CD56+ hematodermic neoplasm.